Sigle et al. evaluated the inhibition of cyclophilin, involved in the mechanisms behind cardiac hypertrophy and remodeling present in heart failure, as a potential therapeutic target to prevent heart failure, examining the structural differences in an in vivo mouse model of angiotensin-II induced heart failure (Sigle et al. This evidence concerns the gene PPIB and heart failure.